Skip to content

Immunovant, Inc. IMVT Other Non-Current Assets

Other Non-Current Assets at other companies

Summit Therapeutics logo
Summit TherapeuticsSMMT
$8.23M+98.6%
TG Therapeutics logo
TG TherapeuticsTGTX
$2.02M-1.3%
Roivant Sciences logo
Roivant SciencesROIV
$40.92M+24.5%
Incyte logo
IncyteINCY
$24.49M-18.8%
Moderna logo
ModernaMRNA
$50M+213%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$7.26B+74.2%
Enterprise value$6.35B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0.0×
Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunovant, Inc.'s other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunovant, Inc.'s other non-current assets?
Immunovant, Inc. (IMVT) reported other non-current assets of $7.68M in Q1 2026.
How has Immunovant, Inc.'s other non-current assets changed year-over-year?
Immunovant, Inc.'s other non-current assets increased by 0.8% year-over-year, from $7.62M to $7.68M.
What does other non-current assets mean?
Long-term assets not classified in specific categories — a catch-all for miscellaneous non-current assets.